Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.67 +0.09 (+0.66%)
Official Closing Price Updated: 7:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,626,158
Open 13.72
Bid (Size) 13.50 (300)
Ask (Size) 13.99 (100)
Prev. Close 13.58
Today's Range 13.57 - 13.83
52wk Range 12.77 - 16.17
Shares Outstanding 166,301,231
Dividend Yield 0.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peter Lynch's GARP Strategy Identifies DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) as a Candidate ↗
Via Chartmill
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Passes Key Peter Lynch Investment Screen ↗
Via Chartmill

Performance

YTD
-1.4%
-1.4%
1 Month
-0.7%
-0.7%
3 Month
-0.8%
-0.8%
6 Month
-5.5%
-5.5%
1 Year
-0.9%
-0.9%

More News

Read More
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy ↗
Via Chartmill
News headline image
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test ↗
Via Chartmill
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Passes Peter Lynch's GARP Investment Filter ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens ↗
Via Chartmill
News headline image
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
From Aurigene Oncology Limited
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Via Chartmill
News headline image
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
Via Chartmill
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
Via Benzinga
Topics Government World Trade
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗
Via Chartmill
News headline image
Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year
Via AB Newswire
Topics Earnings
News headline image
Dr. Reddy’s Q1FY26 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗
Via Chartmill
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire

Frequently Asked Questions

Is Dr. Reddy's Laboratories Ltd Common Stock publicly traded?
Yes, Dr. Reddy's Laboratories Ltd Common Stock is publicly traded.
What exchange does Dr. Reddy's Laboratories Ltd Common Stock trade on?
Dr. Reddy's Laboratories Ltd Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock?
The ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock is RDY on the New York Stock Exchange
What is the current price of Dr. Reddy's Laboratories Ltd Common Stock?
The current price of Dr. Reddy's Laboratories Ltd Common Stock is 13.67
When was Dr. Reddy's Laboratories Ltd Common Stock last traded?
The last trade of Dr. Reddy's Laboratories Ltd Common Stock was at 04/24/26 07:00 PM ET
What is the market capitalization of Dr. Reddy's Laboratories Ltd Common Stock?
The market capitalization of Dr. Reddy's Laboratories Ltd Common Stock is 2.27B
How many shares of Dr. Reddy's Laboratories Ltd Common Stock are outstanding?
Dr. Reddy's Laboratories Ltd Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.